We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AVXL market cap is 279.18M. The company's latest EPS is USD -0.5785 and P/E is -5.88.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -15.38M | -14.19M | -13.53M | -12.65M | -11.29M |
| Net Income | -12.97M | -13.11M | -11.28M | -10.15M | -8.62M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 54k | 0 | 0 |
| Operating Income | -29.11M | -31.09M | -41.95M | -50.99M | -55.76M |
| Net Income | -26.3M | -26.28M | -37.91M | -47.98M | -47.51M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 148.37M | 159.19M | 157.81M | 154.39M | 148.07M |
| Total Liabilities | 13.25M | 14.02M | 11.06M | 12.53M | 12.5M |
| Total Equity | 135.12M | 145.17M | 146.76M | 141.85M | 135.58M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 25.33M | 34.54M | 161.62M | 152.71M | 154.39M |
| Total Liabilities | 5.04M | 7.31M | 10.8M | 10.21M | 12.53M |
| Total Equity | 20.29M | 27.24M | 150.82M | 142.49M | 141.85M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -5.79M | -14.28M | -21.94M | -27.79M | -7.32M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 258k | 18.59M | 27.59M | 29.65M | 59k |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -18.53M | -21.29M | -30.38M | -24.24M | -27.79M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 17.78M | 28.35M | 153.24M | 21.29M | 29.65M |
| Market Cap | 279.18M |
| Price to Earnings Ratio | -5.88 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.85 |
| Price to Book Ratio | 1.97 |
| Dividend Yield | - |
| Shares Outstanding | 82.11M |
| Average Volume (1 week) | 1.56M |
| Average Volume (1 Month) | 1.21M |
| 52 Week Change | -57.55% |
| 52 Week High | 10.45 |
| 52 Week Low | 3.39 |
| Spread (Intraday) | 0.1 (2.86%) |
| Company Name | Anavex Life Sciences Corporation |
| Address |
701 s carson st carson city, nevada 89701 |
| Website | https://www.anavex.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
